As medical technology continues to evolve and provide cutting-edge solutions and treatment to patients, Samsung Electronics Switzerland helps advance the development of its products.
Samsung cooperated with Bottneuro AGMedTech, a new Swiss company dedicated to improving the diagnosis and treatment of Alzheimer’s disease and providing patients with innovative and improved diagnostic and treatment solutions. Bottneuro AG has selected Samsung Galaxy Tab S8+ 5G Enterprise Edition devices to store and record treatment data in the Bottneuro solution.
Powerful treatment through innovative technologies
Bottneuro AG’s technology identifies brain regions affected by the disease through 3D magnetic resonance imaging (MRI) and positron emission tomography (PET) data. Once identified, these areas can be targeted and stimulated electronically with Miamind® Neurostimulation technology. Galaxy Tab S8+ 5G Enterprise Edition simplifies the management of the Bottneuro solution through a graphical interface.
Dementia patients often experience impaired cognitive function in the early stages of the disease, making the need to find a device that is easy to operate and understand essential for Bottneuro AG. With its intuitive interface and ease of use, the Galaxy Tab S8+ 5G Enterprise Edition offered the optimal hardware for Bottneuro’s solution.
“We were looking for a simple and reliable solution for our application. We found it with the Galaxy Tab S8+ 5G Enterprise Edition and Samsung is very supportive of us in development,” said Julius Klass, CTO of Bottneuro AG.
Perfect solutions on a Galaxy tablet
The Galaxy Tab S8+ 5G Enterprise Edition offers a wealth of features and capabilities. It comes with a high-resolution Super AMOLED screen that offers great clarity for both patients and healthcare providers and offers a reliable long-lasting battery.
myamand® The neurostimulator also works directly with the Galaxy Tab S8+ 5G Enterprise Edition and, once the treatment is complete, the Galaxy Tab S8+ automatically transmits the diagnostic and treatment information contained in the Bottneuro solution to Bottneuro AG via a 5G data connection. , allowing patients to stay in the comfort of their own home. . Additionally, the Galaxy Tab S8+ 5G Enterprise Edition can be individually configured via Samsung Knox, keeping sensitive data and medical records private and protected.
Alliances for the future
Such groundbreaking innovations would not be possible without partnerships, and Samsung is proud to have supported and worked with Bottneuro AG since its founding in 2021.
“We are delighted to offer Bottneuro AG a reliable, secure and simple solution with Samsung Knox and to support their new treatment approach,” added Daniel Casella, Head of MX B2B Mobile at Samsung Switzerland.
The efficacy of the new therapeutic treatment from Bottneuro AG will be tested in several clinical studies this year. Although the treatment is not yet commercially available, Bottneuro AG and Samsung remain optimistic about the progress that can be made in treating Alzheimer’s disease.
For more information about Bottneuro AG and the partnership with Samsung, please visit the Samsung Switzerland press room, www.bottneuro.com o www.miamind.com.
